Modular Design of T Cell Nanoengagers for Tumor Immunotherapy via Genetically Engineered Lipid-Tagged Antibody Fragments.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40259502.
- Also identified by DOI 10.1002/adma.202503060.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T cell engagers, which bind tumor-associated antigens and T cell specific molecules, represent a promising class of immunotherapies for enhancing targeted immune responses. Here, a "plug-and-display" platform is introduced for engineering T cell nanoengagers by anchoring antibody fragments into lipid-based nanoparticles. This approach utilizes a genetically engineered lipoprotein fused with single-chain variable fragments (scFv) and nanobodies, which spontaneously integrate into lipid bilayer of the nanoparticles, achieving a high surface density of at least 0.102 scFv nm<sup>-2</sup> (≈3200 scFv per particle). Modular bi-specific (Lipo-BiTE) and tri-specific (Lipo-TriTE) immunoliposomes are designed to enhance anti-tumor T cell immune responses. The Lipo-BiTE, integrating anti-CD3 and anti-HER2 scFv at an optimized surface density of 1.28 × 10<sup>-3</sup> scFv nm<sup>-2</sup>, exhibits enhanced CD8<sup>+</sup> T cell-mediated cytotoxicity in HER2-positive tumor models by simultaneously engaging tumor cells and T cells. Incorporating anti-PD-L1 nanobodies to create Lipo-TriTE further addresses T cell exhaustion. This modular platform provides a robust foundation for designing immune cell engagers, with broad applications in targeted immunotherapy.
Medical subject headings
- Immunotherapy
- Single-Chain Antibodies
- Nanoparticles
- T-Lymphocytes
- Neoplasms
- Genetic Engineering
- Lipids